SAN DIEGO — Ozempic and Wegovy grew to become weight reduction sensations by focusing on a single hormone, main individuals to lose as a lot as 15% of their weight. However that wasn’t sufficient — quickly there was Mounjaro, which targets two hormones, resulting in 21% weight reduction.
Now, Eli Lilly has new outcomes exhibiting that an experimental drug that targets three hormones led to 24.2% weight reduction in a mid-stage trial, the best quantity seen but with an weight problems drug.
The outcomes had been in sufferers who took the best dose of the drug, referred to as retatrutide, and match the excessive finish of the 22%-24% estimate Lilly gave in an investor name final 12 months. If the weekly injectable drug succeeds in bigger Section 3 trials, it might propel Lilly forward of rivals within the heated race to produce the best weight problems therapies.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED